Cytokinetics EVP, Chief Commercial Officer Andrew Callos sells 14,000 common shares for $1.12 million
CYTK•Cytokinetics executive sells shares and exercises options
Cytokinetics EVP and Chief Commercial Officer Andrew Callos sold 14,000 common shares on July 30, 2026 at $79.88.
He exercised 14,000 non-qualified stock options at $23.26 in the same filing.
Directly held common shares fell to 58,555 following the transactions.
Callos reported 10,000 options remaining after the exercise.
